Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RYTM 
Rhythm Pharmaceuticals Inc (RYTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: RYTM (4-star) is a WEAK-BUY. BUY since 143 days. Simulated Profits (65.40%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $121.43
1 Year Target Price $121.43
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 85.88% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.54B USD | Price to earnings Ratio - | 1Y Target Price 121.43 |
Price to earnings Ratio - | 1Y Target Price 121.43 | ||
Volume (30-day avg) 12 | Beta 1.96 | 52 Weeks Range 45.91 - 116.00 | Updated Date 11/7/2025 |
52 Weeks Range 45.91 - 116.00 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.6874 | Actual -0.82 |
Profitability
Profit Margin -117.16% | Operating Margin (TTM) -93.39% |
Management Effectiveness
Return on Assets (TTM) -29.39% | Return on Equity (TTM) -116.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6316677447 | Price to Sales(TTM) 37.7 |
Enterprise Value 6316677447 | Price to Sales(TTM) 37.7 | ||
Enterprise Value to Revenue 40.42 | Enterprise Value to EBITDA -12.65 | Shares Outstanding 66420091 | Shares Floating 54803881 |
Shares Outstanding 66420091 | Shares Floating 54803881 | ||
Percent Insiders 0.65 | Percent Institutions 105.32 |
Upturn AI SWOT
Rhythm Pharmaceuticals Inc
Company Overview
History and Background
Rhythm Pharmaceuticals Inc. was founded in 2008. The company focuses on developing and commercializing therapies for rare genetic diseases of obesity. It's key milestone is the FDA approval and subsequent launch of IMCIVREE for certain genetic obesity disorders.
Core Business Areas
- Genetic Obesity Programs: Focuses on the discovery, development, and commercialization of therapies for rare genetic disorders of obesity. This includes IMCIVREE and other investigational therapies.
- Research and Development: Investing in research and development to expand its pipeline of potential therapies for genetic obesity and related metabolic disorders.
Leadership and Structure
The company is led by a management team with expertise in pharmaceutical development and commercialization. The organizational structure includes departments for research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- IMCIVREE (setmelanotide): IMCIVREE is a melanocortin-4 receptor (MC4R) agonist approved for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing and for patients 6 years of age and older with Bardet-Biedl syndrome (BBS). It's Rhythm's primary revenue driver. Precise market share data is difficult to obtain, but it has a leadership position in treating these rare genetic obesities. Competitors include companies developing weight management therapies, though none directly target the same specific genetic conditions. Potential future gene therapies also pose long-term competition.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on obesity and metabolic disorders is competitive and rapidly evolving, with growing demand for effective therapies. There is increased interest in obesity medicine.
Positioning
Rhythm Pharmaceuticals is a leader in the niche area of genetic obesity, having a significant advantage in rare obesity disorders with its MC4R agonist. Its future market is in expanding the use of MC4R agonists.
Total Addressable Market (TAM)
The TAM for genetic obesity is significant, estimated in the hundreds of millions to billions of dollars, considering the unmet need and potential for future expansion to other genetic obesity conditions. Rhythm is positioned to capture a substantial portion of this market given its current approved product and pipeline.
Upturn SWOT Analysis
Strengths
- First-mover advantage in genetic obesity treatments
- Approved product (IMCIVREE)
- Strong intellectual property portfolio
- Dedicated focus on rare genetic diseases
Weaknesses
- Reliance on a single product
- High R&D expenses
- Limited market size due to the rarity of targeted diseases
- Commercial execution dependent on genetic testing access and reimbursement challenges.
Opportunities
- Expanding IMCIVREE's indications to other genetic obesity disorders
- Developing new therapies for related metabolic disorders
- Collaborating with other pharmaceutical companies
- Geographic expansion
Threats
- Competition from other weight management therapies
- Regulatory hurdles
- Reimbursement challenges
- Patent expiration
- Failure of clinical trials for pipeline products
Competitors and Market Share
Key Competitors
- NVO
- LLY
- VKTX
Competitive Landscape
Rhythm has a significant advantage in genetic obesity, but faces competition in the broader weight management market from established pharmaceutical companies with broader therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by the commercial launch of IMCIVREE and expansion into new markets.
Future Projections: Future growth depends on expanding IMCIVREE's indications, regulatory approvals for pipeline products, and sales execution. Analyst estimates depend on these factors.
Recent Initiatives: Recent initiatives include clinical trials for additional indications of setmelanotide, efforts to expand access to genetic testing, and strategic partnerships.
Summary
Rhythm Pharmaceuticals is a promising biopharmaceutical company with a focus on rare genetic obesity disorders. Its key product, IMCIVREE, has established it as a leader in its niche, but the company's reliance on a single product and its limited market size pose challenges. Future growth depends on expanding IMCIVREE's indications, successful development of its pipeline, and effective commercialization. Competition from established players in the broader weight management market is a risk the company needs to watch out for.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Rhythm Pharmaceuticals Inc. investor relations
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial information is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rhythm Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-10-05 | Chairman, President & CEO Dr. David P. Meeker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 283 | Website https://rhythmtx.com |
Full time employees 283 | Website https://rhythmtx.com | ||
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.